Skip to main content

Table 4 Characteristics associated with 28-day mortality among patients who received intravenous PMB

From: Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Parameter

Value for:

P

Survivors (n = 60)

Nonsurvivors (n = 40)

Age, y, mean ± SD

54.65 ± 16.23

57.8 ± 18.45

0.370

Female, n (%)

47 (78.3)

32 (80.0)

0.840

WBC, × 109/L, median (IQR)

14.28 (10.58, 20.44)

13.84 (9.55, 19.65)

0.359

PLT, × 109/L, mean ± SD

131.37 ± 101.96

71.15 ± 66.27

0.001

PCT, ng/ml, median (IQR)

2.30 (0.70, 10.07)

5.00 (1.97, 15.93)

0.062

CRP, ug/l, median (IQR)

100.15 (50.70, 174.33)

119.96 (79.58, 186.0)

0.624

SOFA, mean ± SD

6.77 ± 4.07

9.25 ± 4.25

0.004

APACHE II, mean ± SD

16.17 ± 7.80

19.78 ± 6.80

0.016

Mechanical ventilation, n (%)

21 (35.0)

30 (75.0)

< 0.001

Septic shock, n (%)

17 (28.3)

32 (80.0)

< 0.001

Hospitalization before intravenous PMB, days, median (IQR)

12.00 (5.25, 20.75)

11.50 (3.25, 21.00)

0.882

ICU stay before intravenous PMB, days, median (IQR)

9.00 (3.00, 15.00)

5.00 (1.00, 14.00)

0.156

Treatment duration, days, median (IQR)

11.00 (9.00, 13.00)

10.00 (8.25, 13.75)

0.697

Concomitant antibiotic therapy, n (%)

0.844

 PMB + Carbapenem

19 (31.67)

11 (27.5)

 

 PMB + Carbapenem + Tigecycline

16 (26.67)

10 (25)

 

 PMB + Tigecycline

6 (10)

5 (12.5)

 

 PMB + Cephalosporin

4 (6.67)

5 (12.5)

 

 PMB + Carbapenem + Cephalosporin

4 (6.67)

4 (10)

 

 Others

11 (18.33)

5 (12.5)

 

Daily dose of PMB, mg/day, n (%)

0.425

 100

35 (58.33)

18 (45)

 

 150

9 (15)

8 (20)

 

 200

16 (26.67)

14 (35)

 

Identify microorganisms, n (%)

52 (86.67)

33 (82.5)

0.580

KP, n (%)

32 (53.3)

16 (40.0)

0.191

AB, n (%)

19 (31.7)

14 (35)

0.728

Multisite infection, n (%)

20 (33. 3)

15 (37.5)

0.669

Pulmonary infection, n (%)

35 (58.3)

29 (72.5)

0.217

BSI, n (%)

26 (43.3)

14 (35.0)

0.405

Chronic medical conditions, n (%)

45 (75.0)

32 (80.0)

0.734

Nephrotoxicity, n (%)

13 (21.7)

13 (32.5)

0.251

Adverse reactions, n (%)

8 (13.3)

8 (20.0)

0.373

  1. Categorical variables are presented as numbers (%), and continuous variables are presented as mean ± SD or interquartile ranges [IQR]
  2. WBC: white blood cell; PLT: platelet count; PCT: procalcitonin; CRP: C-reactive protein; SOFA: Sequential Organ Failure Assessment; APACHEII: Acute Physiology and Chronic Health Evaluation II; PMB: polymyxin B; ICU: intensive care unit; KP: Klebsiella pneumoniae; AB: Acinetobacter baumannii; BSI: Bloodstream Infection; SD: standard deviation
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us